IP Library Granted Patent US 11,679,028
Granted Patent B2
US 11,679,028 · App. 16/811,879 · Granted Jun 20, 2023

Multi-dose ocular fluid delivery system

Inventors: Reynaldo Quintana (Menlo Park, CA); Yehuda Ivri (Newport Coast, CA)
Assignee: Novartis AG
A61F9/0026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,679,028
App. No.
16/811,879
Granted
Jun 20, 2023
Kind
B2
Abstract

Multi-dose ocular fluid delivery devices are provided. Aspects of the fluid delivery devices include a fluid package and an actuator. The fluid package includes a reservoir of an ophthalmic formulation, an aperture and a valve member for sealing the aperture when fluid is not being ejected therethrough. The actuator is configured to operate the valve member so as to at least reduce, if not prevent, ingress of outside materials or contaminants into the reservoir, such that the ophthalmic formulation present in the reservoir does not require a preservative (e.g., where a preservative-free ophthalmic formulation is present in the reservoir). Also provided are methods of using the devices in fluid delivery applications, as well as a kit that includes components of the devices.

Claims (18)

1. An apparatus for deliver a fluid to an eye of a patient, the apparatus comprising:

a fluid package comprising a reservoir configured to hold a fluid, an aperture, and a valve member configured to seal the aperture when fluid is not being ejected through the aperture;

an actuator configured to eject the fluid through the aperture by providing a mechanical vibration to the valve member and/or to a wall of the reservoir;

wherein the fluid package comprises a resilient diaphragm configured to hold a tip of the valve member in engagement with the aperture when fluid is not being ejected through the aperture;

wherein the valve member is affixed to the resilient diaphragm;

wherein the actuator provides the mechanical vibration by driving motion of a connecting member connecting the actuator to the valve member.

2. The apparatus of claim 1 , wherein the actuator is configured to eject the fluid from the aperture by vibrating a tip of the valve member into and out of engagement with the aperture.

3. The apparatus of claim 1 , wherein the actuator is configured to generate pressure fluctuations in the fluid sufficient to eject the fluid through the aperture and past the valve member.

4. The apparatus of claim 1 , wherein the fluid is a preservative-free ophthalmic solution.

5. The apparatus of claim 1 , wherein the reservoir is a multi-dose reservoir.

6. The apparatus of claim 1 , wherein the valve member has a conical tip that engages with the aperture.

7. The apparatus of claim 1 , wherein the valve member has a rounded tip that engages with the aperture.

8. The apparatus of claim 1 , wherein the valve member has a tip that engages with the aperture, and wherein the tip comprises an anti-microbial material.

9. The apparatus of claim 1 , wherein the aperture comprises an anti-microbial material.

10. The apparatus of claim 1 , wherein the actuator comprises an electromagnetic transducer disposed on an external surface of the reservoir and configured to induce vibration of at least part of a wall of the reservoir.

11. The apparatus of claim 10 , wherein the actuator is configured to eject fluid from the aperture by generating pressure fluctuations in the fluid due to the vibration.

12. The apparatus of claim 1 , wherein the apparatus is configured to deliver a dose volume of 1 to 15 μl.

13. The apparatus of claim 1 , wherein the apparatus is configured to deliver a dose in 150 ms or less.

Assignments (8)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (066694/0131) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0655 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 29, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066707/0684 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 27, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 066694/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: NOVARTIS AG
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 065531/0583 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT AGREEMENT PREVIOUSLY RECORDED ON REEL 062116 FRAME 0917. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 10, 2023
From: KEDALION THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 064237/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2022
From: KEDALION THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 062116/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: QUINTANA, REYNALDO; IVRI, YEHUDA
To: KEDALION THERAPEUTICS, INC.
Reel/Frame 052593/0315 →
Continuity (3)
Provisional Application 62951903 · Dec 20, 2019
Provisional Application 62814773 · Mar 6, 2019
Related Publication 20200281768A1 · Sep 10, 2020
Cited By (2)
US 12,667,485 US 12,698,132